Patents by Inventor Kenju Miura
Kenju Miura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7282201Abstract: This invention has as its object providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors which are useful as therapeutics of diseases that result from insufficient growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors, in particular, as therapeutics of panhematopenia and/or diseases that are accompanied by hematopoietic hypofunction. The invention attains the stated object by providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors that contain Cofilin as an active ingredient.Type: GrantFiled: August 28, 2003Date of Patent: October 16, 2007Assignee: Asubio Pharma Co., Ltd.Inventors: Kenju Miura, Munetada Haruyama, Shiho Kodama
-
Publication number: 20040156847Abstract: Herein disclosed are therapeutic agents for hypereosinophilic diseases comprising a substance inducing eosinophil apoptosis via CD30 and/or a molecule involved in CD30 signal transduction as an active ingredient. Such therapeutic agents are effective for allergic diseases, respiratory diseases, skin diseases, autoimmune diseases, immunodeficiency diseases, digestive diseases, neoplastic diseases and parasitic infections.Type: ApplicationFiled: December 19, 2003Publication date: August 12, 2004Applicants: DAIICHI SUNTORY PHARMA CO., LTD., DAIICHI SUNTORY BIOMEDICAL RESEARCH, LTD.Inventors: Kenju Miura, Maki Matsubayashi, Hirohisa Saito, Kenji Matsumoto
-
Publication number: 20040157326Abstract: This invention has as its object providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors which are useful as therapeutics of diseases that result from insufficient growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors, in particular, as therapeutics of panhematopenia and/or diseases that are accompanied by hematopoietic hypofunction. The invention attains the stated object by providing promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors that contain Cofilin as an active ingredient.Type: ApplicationFiled: August 28, 2003Publication date: August 12, 2004Applicants: DAIICHI SUNTORY PHARMA CO., LTD., DAIICHI SUNTORY BIOMEDICAL RESEARCH, LTD.Inventors: Kenju Miura, Munetada Haruyama, Shiho Kodama
-
Publication number: 20020164711Abstract: A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host.Type: ApplicationFiled: March 7, 2002Publication date: November 7, 2002Inventors: Masafumi Tsujimoto, Fuyuki Iwasa, Nobuo Tsuruoka, Hiroshi Nakazato, Kenju Miura, Nobuhiro Ishida, Tatsuya Kurihara, Kozo Yamaichi, Nozomi Yamaguchi
-
Publication number: 20010026931Abstract: A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host.Type: ApplicationFiled: August 26, 1998Publication date: October 4, 2001Inventors: MASAFUMI TSUJIMOTO, FUYUKI IWASA, NOBUO TSURUOKA, HIROSHI NAKAZATO, KENJU MIURA, NOBUHIRO ISHIDA, TATSUYA KURIHARA, KOZO YAMAICHI, NOZOMI YAMAGUCHI
-
Patent number: 6040335Abstract: Compounds represented by the general formula (I) or pharmacologically acceptable salts thereof: ##STR1## (where R is a group --NHCHR.sub.1 R.sub.2, --N(CHR.sub.1 R.sub.2).sub.2, --N(CHR.sub.1 R.sub.2)CHR.sub.3 R.sub.4, --N.sup.+ (CHR.sub.1 R.sub.2).sub.3, --N.sup.+ (CHR.sub.1 R.sub.2).sub.2 CHR.sub.3 R.sub.4 or --N.sup.+ (CHR.sub.1 R.sub.2)(CHR.sub.3 R.sub.4)CHR.sub.5 R.sub.6 (where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6, which may be the same or different, are each a hydrogen atom, an alkyl group, an alkenyl group, an aryl group or an aralkyl group, or an alkyl, alkenyl, aryl or aralkyl group which is substituted by at least one substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkylacyloxy group, a lower alkylacyl group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a heterocyclic group, with CHR.sub.1 R.sub.2, CHR.sub.3 R.sub.4 or CHR.sub.5 R.sub.Type: GrantFiled: July 31, 1997Date of Patent: March 21, 2000Assignee: Suntory LimitedInventors: Masayuki Saitoh, Yasuo Kitajima, Norio Iwasawa, Kenju Miura, Munetada Haruyama, Junko Hashino
-
Patent number: 5972886Abstract: A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host.The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.Type: GrantFiled: March 6, 1996Date of Patent: October 26, 1999Assignee: Suntory LimitedInventors: Masafumi Tsujimoto, Fuyuki Iwasa, Nobuo Tsuruoka, Hiroshi Nakazato, Kenju Miura, Nobuhiro Ishida, Tatsuya Kurihara, Kozo Yamaichi, Nozomi Yamaguchi
-
Patent number: 5874253Abstract: A novel megakaryocyte differentiation factor, for example, consisting essentially of SEQ ID NO: 30; DNA coding for the megakaryocyte differentiation factor, an expression vector comprising the DNA, a host transformed with the expression vector, and a process for production of the megakaryocyte differentiation factor using the host. The megakaryocyte differentiation factor accelerates differentiation of megakaryocytes in the presence of IL-3, and acts as a thrombopoietin, and therefore an effective medicament to various diseases involving a decrease in platelete.Type: GrantFiled: June 7, 1995Date of Patent: February 23, 1999Assignee: Suntory LimitedInventors: Masafumi Tsujimoto, Fuyuki Iwasa, Nobuo Tsuruoka, Hiroshi Nakazato, Kenju Miura, Nobuhiro Ishida, Tatsuya Kurihara, Kozo Yamaichi, Nozomi Yamaguchi
-
Patent number: 5831030Abstract: The present invention provides novel megakaryocyte differentiation factors, which are useful as therapeutic agents due to their accelerating effects on the differentiation of megakaryocytes and their thrombopoietic effects. The megakaryocyte differentiation factors of the present invention include the megakaryocyte differentiation factor having the amino acid sequence shown in SEQ ID NO: 34. The present invention also provides DNA coding for the megakaryocyte differentiation factors of the present invention, expression vectors containing the DNA, hosts transformed with the expression vectors, and processes for production of the megakaryocyte differentiation factors using transformed hosts. The present invention further provides specific antibodies to the megakaryocyte differentiation factors of the present invention.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignee: Suntory LimitedInventors: Masafumi Tsujimoto, Fuyuki Iwasa, Nobuo Tsuruoka, Hiroshi Nakazato, Kenju Miura, Nobuhiro Ishida, Tatsuya Kurihara, Kozo Yamaichi, Nozomi Yamaguchi
-
Patent number: 5126253Abstract: A novel cell line for use as a parent for hybridoma preparation is provided. This cell line is derived from tumor cells, in particular human tumor cells, other than those originating from bone marrow cells. A method for establishing this cell line is also provided. By fusing this cell line with cells producing useful physiologically active substances, such as B cells immunized with an antigen, a hybridoma capable of active growth can be prepared. This hybridoma can be cultivated for the production of useful physiologically active substances.Type: GrantFiled: September 25, 1986Date of Patent: June 30, 1992Assignee: Suntory LimitedInventors: Toshihiro Nakanishi, Masashi Matsui, Kenju Miura, Yoshiaki Fukuda, Teruhisa Noguchi
-
Patent number: 4820641Abstract: The specification discloses a monoclonal antibody capable of distinguishing human hepato-carcinoma cells, a hybridoma producing said monoclonal antibody and a process for preparing the monoclonal antibody using said hybridoma. The monoclonal antibody of the invention specifically attackes hepato-carcinoma cells in vivo.Type: GrantFiled: June 27, 1985Date of Patent: April 11, 1989Assignee: Suntory LimitedInventors: Toshihiro Nakanishi, Yoshiaki Fukuda, Kenju Miura, Hiroshi Nakazato